How can we improve the environmental impact of cancer care in the growing context of climate change and worldwide ecological issues?
 

In proton therapy, the design of the system significantly influences key beam parameters, and can have a direct impact on patient care. Thus, it is important to understand beam quality's role in radiotherapy and cancer treatment.​

As a hospital executive, head of the radiotherapy department, radiation oncologist, medical physicist or radiotherapist, you may wonder if adding proton therapy treatment to your radiation oncology department can increase your hospital’s attractivity, improve cancer patient experience, and contribute to talent attraction and retention. ​

In the evolving landscape of cancer treatment, proton therapy stands out as a revolutionary approach, particularly for patients with unique tumor circumstances. Dr. Peter Johnstone, a radiation oncologist at Moffitt Cancer Center in Tampa, Florida, highlights the powerful benefits of partnering with IBA to enhance patient care through innovative proton therapy solutions. This article explores the insights shared by Dr. Johnstone regarding the IBA partnership for today and tomorrow, focusing on the advantages of proton therapy and the collaborative journey ahead. 

Dr. Lane Rosen, Director of Radiation Oncology at Willis Knighton Cancer Center in Shreveport, Louisiana, highlights the transformative impact of introducing proton therapy with the ProteusONE system at their facility. In this blog, he shares insights into how a community hospital can successfully implement proton therapy, traditionally reserved for larger academic centers. 

Proton Arc Therapy with DynamicARC* is on the verge of transforming the landscape of proton therapy and cancer care. In this blog, Xuanfeng (Leo) Ding, PhD, the Lead Proton Physicist at Corewell Health’s William Beaumont University Hospital Proton Therapy Center, explains how DynamicARC* will revolutionize the proton therapy field with its advanced capabilities, representing the next leap forward in cancer treatment technology. 

Proton therapy represents a significant advancement in radiation oncology. In this article, Dr. Craig Stevens, Chair of Radiation Oncology at Corewell Health’s William Beaumont University Hospital Proton Therapy Center, discusses the evolution and benefits of their ProteusONE system installed in 2017.  

The University of Kansas Cancer Center has significantly enhanced patient care and institutional growth by integrating proton therapy into their treatment options. As a National Cancer Institute (NCI) designated Comprehensive Cancer Center, they recognized the need for advanced particle beam treatments for the diverse patient population they serve, particularly for their pediatric cancer patients. Darin Kistler, Senior Director of Radiation Services, describes the center's evolution since installing the ProteusONE proton therapy system in 2017. 

DynamicARC promises to revolutionize proton therapy by providing faster, sharper and simpler treatments to enhance patient care. In this blog, Dr. Rohan Deraniyagala, Medical Director at William Beaumont Hospital, part of the Corewell Health System, explains the advantages of this innovative technology, highlighting its ability to provide quicker treatments as a primary benefit for cancer patients. Patients undergoing proton therapy with DynamicARC can find themselves on the treatment table for less time, which is a critical factor in their overall experience and comfort.^1,2 The faster treatment may also result in increased efficiency, allowing hospitals to accommodate a higher throughput of patients, making a real difference in cancer care accessibility.³  

DynamicARC* represents a pivotal breakthrough in radiation therapy and in cancer treatment. In this blog, Dr. Craig Stevens, Professor and Chair of the Department of Radiation Oncology at William Beaumont Hospital, part of the Corewell Health System, emphasizes to what extent DynamicARC is key to the future of radiation therapy with protons, enabling a paradigm shift in cancer treatment.  

Prof. Barbara Alicja Jereczek-Fossa is Chair of Radiation Oncology at the European Institute of Oncology (IEO) in Milan and full Professor at the University of Milan, in Italy. She was elected President of the European Society for Radiotherapy and Oncology (ESTRO) in 2024 and her term is set to begin in 2026. ESTRO’s mission is to reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. Prof. Jereczek-Fossa, a highly respected radiation oncologist, brings decades of clinical experience, institutional leadership at the IEO, and a powerful vision for expanding access to precision therapies like proton therapy worldwide. This article highlights her view on proton therapy and the future of precision cancer care. 

Find out how ProteusONE at IEO Milan combines precision, patient comfort, and future-ready technology to set new standards in cancer care.